FDA prohibits importation of 28 prescription drugs from India

09/16/2008 | Washington Post, The · Reuters

The FDA announced that it is banning 28 prescription drugs from Ranbaxy Laboratories after discovering production lapses at two of the generic-drug firm's facilities in India. An agency official said there was "no evidence of harm to consumers" based on contamination tests. Ranbaxy expressed disappointment with the decision, saying it responded to all concerns that the FDA raised during the past two years.

View Full Article in:

Washington Post, The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY